FindTrial
Sign In

Pharmacogenetics research of the PBMC cytotoxicity and anti-breast cancer activity mediated by CD3/HER2 bispecific antibody

Pharmacogenetics research of the PBMC cytotoxicity and anti-breast cancer activity mediated by CD3/HER2 bispecific antibody

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-16008650
Enrollment
Unknown
Registered
2016-06-15
Start date
2016-06-28
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

control group, M802 group, Herceptin group:NA

Sponsors

Department of Clinical Pharmacology, Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Healthy crowd, aged 15-45 years; 2. Patients with early breast cancer, without radiation and chemotherapy experiences

Exclusion criteria

Exclusion criteria: 1. Unhealthy or age not between 18 to 45; 2. Not breast cancer patients or have the experiences with radiation or chemotherapy

Design outcomes

Primary

MeasureTime frame
Cytotoxicity;—

Countries

China

Contacts

Public ContactChen Xiaoping

Department of Clinical Pharmacology, Xiangya Hospital, Central South University

chenxp74@hotmail.com+86 13875803018

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026